Abstracts Archive - Page 166 of 2607 - ACR Meeting Abstracts

Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Minyun Zhou¹, Peng Gu², Mengyu Wang³, Yuxi Yan², Li Sun³, Yiling Chen³, Xin Wang³, Feng Tang¹, Shunwei Zhu² and Xiaofeng Zhao⁴, ¹State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
Abstract Number: 0632 • ACR Convergence 2025
Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study
Rusudan Tskitishvili¹, Abdallah Hussein², Roman Karagulyan², Shatha Shahwan³ and Priju Varghese², ¹Virtua Health, Camden, NJ, ²Virtua Health, Camden, ³Jordan University of Science and Technology, Jordan
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a heightened risk of cardiovascular and renal complications, particularly in patients with comorbid diabetes mellitus. While both…
Abstract Number: 0910 • ACR Convergence 2025
Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
MIN GANG KIM¹, JINA YEO², HEA RIM KANG³, JAE HYUN MOON³, Seon Uk Kim⁴, SeoYoon Ban⁵, MI HYEON KIM⁶ and Eun Young Lee⁷, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁴Seoul National University, Jongno-gu, Seoul, Republic of Korea, ⁵Department of Cancer biology, Graduate School of College of Medicine, Seoul National University, Korea, Seoul, Republic of Korea, ⁶Hallym university dongtan sacred heart hospital, Seocho-gu, Seoul, Republic of Korea, ⁷Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: IgG4-related disease (IgG4RD) is an immune-mediated fibroinflammatory condition characterized by multi-organ involvement, elevated serum IgG4, and IgG4-positive plasma cell infiltrates that form tumor-like lesions…
Abstract Number: 0693 • ACR Convergence 2025
Impact of X Chromosome Dosage on the Development of Diffuse and Limited Systemic Sclerosis in Klinefelter, Triple X, and Turner Syndromes: A Multicenter Cohort Study
Hanieh Akbari¹, Anna-Kay Palmer² and Irene Tan³, ¹Jefferson Einstein Montgomery Medical Center, Norristown, PA, ²Jefferson Einstein Philadelphia Hospital, Department of Internal Medicine, Philadelphia, PA, ³Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Diffuse and limited systemic sclerosis (SSc) are autoimmune connective tissue diseases with a strong female predominance, suggesting a potential role for X chromosome dosage…
Abstract Number: 0569 • ACR Convergence 2025
ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
Floris A. van Gaalen¹, Victoria Navarro-Compan², Xenofon Baraliakos³, Filip Van den Bosch⁴, Lianne S. Gensler⁵, Ihsane Hmamouchi⁶, Robert Landewé⁷, Pedro Machado⁸, Helena Marzo-Ortega⁹, Valeria Rios Rodriguez¹⁰, Denis Poddubnyy¹¹, Sofia Ramiro¹² and Désirée Van Der Heijde¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, ⁷Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁹NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹⁰Charité-Universitétsmedizin Berlin, corporate member of Freie universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ¹¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The recently updated Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS)includes an agreed minimum set of instruments that should be used in…
Abstract Number: 0935 • ACR Convergence 2025
Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Brianna Thompson², Vanessa Manada De Lobos² and Carla Marie Cuda³, ¹Northwestern University, Elmhurst, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (anxiety, cognitive dysfunction) lead to the devastating impact of this disease on patients’ health-related quality-of-life. Dysbiosis of gut microbiota…
Abstract Number: 0925 • ACR Convergence 2025
Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
Megan M. Hanlon¹, Catherine Manning¹, Kevin Wei¹, Ursula Fearon² and Ellen M. Gravallese³, ¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²Trinity College Dublin, Dublin, Dublin, Ireland, ³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Synovial tissue macrophages (STMs) represent a mixed population of cells contributing to the pathogenesis of rheumatoid arthritis (RA). We identified an enrichment of Secreted…
Abstract Number: 0948 • ACR Convergence 2025
Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease
Lance Peterson¹, Hannah KL De Cleene², Cheryl Lichti², David Bending³ and Kodi Ravichandran², ¹Rheumatology and Immunology, Pediatrics, Washington University School of Medicine, St. Louis, MO, ²Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, ³Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, United Kingdom
Background/Purpose: Systemic lupus erythematosus is a chronic, multisystem autoimmune disease characterized by the dysregulated clearance of dying cells, which results in the release of damage-associated…
Abstract Number: 0952 • ACR Convergence 2025
Therapeutic Potential of PaPE-1 in Reducing TLR7-Mediated Inflammation in a Murine Model of Lupus
Rachael Werner¹, Jena Wirth¹, Gary Gilkeson¹ and Melissa Cunningham², ¹Medical University of South Carolina, Charleston, SC, ²Medical University of SC, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects women, underscoring the critical role of sex chromosomes and sex hormones—particularly estrogen—in…
Abstract Number: 0567 • ACR Convergence 2025
Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Atul Deodhar¹, Laure Gossec², Philip J. Mease³, Xenofon Baraliakos⁴, Lihi Eder⁵, Alan Kivitz⁶, Helena Marzo-Ortega⁷, Frank Behrens⁸, Ana-Maria Orbai⁹, Georg Schett¹⁰, Arthur Kavanaugh¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ⁸Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University of California, San Diego, School of Medicine, San Diego, CA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation.…
Abstract Number: 0701 • ACR Convergence 2025
Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort
Maximiliano Diaz Menindez¹, Simran Ravindra Nimal², Michael Pham², Caroyln Harvey³, Leroy W. Griffing² and Vivek Nagaraja², ¹Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ²Mayo Clinic, Scottsdale, AZ, ³Mayo Clinic, Phoenix, AZ
Background/Purpose: Calcinosis is a vexing manifestation in patients with systemic sclerosis (SSc) with a variable prevalence among cohorts. Up to 86% of calcinosis cases are…
Abstract Number: 0936 • ACR Convergence 2025
Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE
Doaa Tehawey¹, Roni Gattegno², Baruh Polis¹, Mike Bismuth², Melodie Zaknoun¹, Tali Ilovitsh² and Chaim Putterman³, ¹Azrieli Faculty of Medicine, Safed, Israel, ²Tel Aviv University, Tel-Aviv, Israel, ³Albert Einstein College of Medicine, Safed, Israel
Background/Purpose: Neuropsychiatric SLE (NPSLE) is a severe complication of SLE, characterized by CNS involvement leading to cognitive, behavioral, and neurological deficits. While monoclonal antibodies may…
Abstract Number: 0652 • ACR Convergence 2025
Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Brandon Jackson¹, Saira Sheikh², Roberto Caricchio³, Taylor Irons⁴, Maria Dall'Era⁵, Amit Saxena⁶, Alfred Kim⁷, Jose Rubio⁸, Sasha Bernatsky⁹, David Goddard¹⁰, Fotios Koumpouras¹¹, Aimee Williams¹², Maya Merrell¹³, Jennifer Meriwether¹⁴ and Stacie Bell¹⁵, ¹Lupus Therapeutics, Miami, FL, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Lupus Therapeutics, Houston, TX, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Washington University School of Medicine, St. Louis, MO, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰NYU Langone Grossman SOM, Brooklyn, NY, ¹¹Yale School of Medicine, New Haven, CT, ¹²Lupus Therapeutics, Raleigh, NC, ¹³Lupus Therapeutics, Charleston, SC, ¹⁴Lupus Therapeutics, Westminster, CO, ¹⁵Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the premier North American Lupus Clinical Investigators Network (LuCIN). As cell therapy…
Abstract Number: 0959 • ACR Convergence 2025
Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
Bich Na Choi¹, Claudia Pedroza², Brian Skaug³, Maureen Mayes⁴ and Shervin Assassi⁵, ¹UTHealth Houston Institute for Clinical Research & Learning Health Care, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴UT Health Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…
Abstract Number: 0960 • ACR Convergence 2025
Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Cuong Tran-Manh¹, Thuong Trinh-Minh², Christoph Liebel³, Bas van der Woning⁴, Piotr Zabrocki⁵ and Jörg Distler⁶, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Nordrhein-Westfalen, Germany, ²Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴argenx BV, Boston, MA, ⁵argenx, Ghent, Belgium, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: SSc is a rare, chronic, systemic autoimmune rheumatic disease characterized by progressive skin and internal organ fibrosis, severe vasculopathy and immune dysregulation with production…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].